| Name | Title | Contact Details |
|---|
Aesculap is a Center Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PENTAX Medical is a division of Hoya Group. Its mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. Through leading-edge R&D and manufacturing, PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community. Headquartered in Japan, PENTAX Medical has a worldwide focus and presence with R&D, regional sales, service, and in-country facilities around the globe. PENTAX Medical employees represent the diverse countries where we do business, allowing us to provide innovative solutions tailored to meet local needs.
Noir Laser Co LLC is a South Lyon, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dialyze Direct provides staff assisted home hemodialysis services to elderly patients with End Stage Renal Disease who reside in Nursing Homes. Our mission is to deliver innovative and compassionate dialysis care to geriatric patients in Skilled Nursing Facilities, enhancing their quality of life while significantly reducing overall costs by improving outcomes, eliminating transportation and minimizing re-hospitalizations. The Dialyze Direct program permits an unprecedented degree of on-site coordination of care and sharing information with the nursing home staff, with respect to ESRD care, that include nursing, dietary and social work collaboration. Dialyze Direct has re-purposed home dialysis technology, with enhanced and proprietary protocols that are better suited to the special needs of geriatric patients with multiple co-morbid conditions resulting in improved outcomes, shortened recovery times, increased rehab score gains and decreased re-hospitalizations.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.